“It’s not all about the disease”: do treatment and socioeconomic status affect perceived impact and satisfaction of patients treated for cutaneous leishmaniasis?
Authors:
- Carolina Di Pietro CarvalhoCCCarolina Di Pietro Carvalho
- João Gabriel Guimarães LuzJLJoão Gabriel Guimarães Luz
- Amanda Gabriela de CarvalhoACAmanda Gabriela de Carvalho
- Renata Di Pietro CarvalhoRCRenata Di Pietro Carvalho
- Herton Helder Rocha PiresHPHerton Helder Rocha Pires
- João Victor Leite DiasJDJoão Victor Leite Dias
Open Access
- 1 January 2023
- journal article
- research article
- Published by FapUNIFESP (SciELO) in Revista da Sociedade Brasileira de Medicina Tropical
- Vol. 56, e0253
Abstract
This cross-sectional study compared the general impact of cutaneous leishmaniasis (CL) and patient satisfaction with treatment and health services as perceived by those undergoing different therapeutic regimens in an endemic region in South-Eastern Brazil. We also investigated the factors associated with both outcomes (general impact and satisfaction). We included 84 patients with CL treated between 2018 and 2019 with intravenous meglumine antimoniate, liposomal amphotericin B, or intralesional meglumine antimoniate therapy. Data were collected through interviews that assessed sociodemographic characteristics, comorbidity status, access and use of health services for CL diagnosis and treatment, and the items of the Cutaneous Leishmaniasis Impact Questionnaire (CLIQ). The CLIQ is a psychometric questionnaire previously validated to assess the general impact of CL on patient satisfaction with treatment and health services. Multivariate logistic regression analysis was used to identify the factors associated with high CL impact and low patient satisfaction. The general impact of CL and patient satisfaction with treatment and health services were not significantly associated with the therapeutic regimen. High CL impact was associated with low family income (odds ratio [OR]:3.3; 95% confidence interval [CI]:1.0-10.3), occurrence of complications/adverse effects during treatment (OR:7.7; 95%CI:2.4-25.6), and additional costs during diagnosis and/or treatment (OR:12.1; 95% CI:2.8-52.4). Low satisfaction was associated with high disease impact (OR: 9.5; 95% CI:2.7-33.9), occurrence of complications/adverse effects (OR:4.2; 95% CI:1.3-13.0), and high family income (OR:7.1; 95%CI:1.7-28.2). Our data support public health policies aimed at reducing the impact of CL and its treatment as well as the use of therapy with fewer adverse effects.Keywords
This publication has 17 references indexed in Scilit:
- Development and initial validation of a cutaneous leishmaniasis impact questionnairePLOS ONE, 2018
- A new perspective on cutaneous leishmaniasis—Implications for global prevalence and burden of disease estimatesPLOS Neglected Tropical Diseases, 2017
- Eliminating the Neglected Tropical Diseases: Translational Science and New TechnologiesPLOS Neglected Tropical Diseases, 2016
- Social and Economic Burden of Human LeishmaniasisThe American Journal of Tropical Medicine and Hygiene, 2016
- PANCREATIC TOXICITY AS AN ADVERSE EFFECT INDUCED BY MEGLUMINE ANTIMONIATE THERAPY IN A CLINICAL TRIAL FOR CUTANEOUS LEISHMANIASISRevista do Instituto de Medicina Tropical de São Paulo, 2016
- Neglected Tropical Skin DiseasesJAMA Dermatology, 2014
- Is the negative evaluation of dental services among the Brazilian elderly population associated with the type of service?Revista Brasileira de Epidemiologia, 2014
- Estudo clínico randomizado comparando antimoniato de meglumina, pentamidina e anfotericina B para o tratamento da leishmaniose cutânea ocasionada por Leishmania guyanensisAnais Brasileiros de Dermatologia, 2011
- Avanços no tratamento da leishmaniose tegumentar do novo mundo nos últimos dez anos: uma revisão sistemática da literaturaAnais Brasileiros de Dermatologia, 2011
- Systematic review of the adverse effects of cutaneous leishmaniasis treatment in the New WorldActa Tropica, 2011